Shots:
- The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, including giving visibility to the benefits of a new mealtime insulin
- HCPs treating T1D & T2D will be able to assess their patient’s glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, helping them to manage PPG levels. The companies will enhance HCPs education by sharing information about Lyumjev & Dexcom G6 & G6 Pro via different channels
- Lyumjev is a formulation of insulin lispro, act by speeding up the absorption of insulin in the bloodstream and reduce A1C levels in adults with diabetes and has received the US FDA’s approval on Jun 15, 2020
Click here to read full press release/ article | Ref: PRN | Image: IntraMed
The post Eli Lilly Collaborates with Dexcom for Diabetes Management first appeared on PharmaShots.
